Business Context and Reporting Period
This Form 8-K Current Report was filed by Apogee Therapeutics, Inc. on April 21, 2026. The report discloses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
On April 21, 2026, Andrew Gottesdiener, M.D., and Peter Harwin notified the Board of their intention to resign, effective May 11, 2026. Consequently, the Board size will be reduced from nine directors to seven. The Company states these resignations are not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed beyond the standard disclosure of the director departures.
Key Facts for Investors
- Two directors, Andrew Gottesdiener, M.D., and Peter Harwin, are resigning effective May 11, 2026.
- The Board of Directors will shrink from nine to seven members.
- Management confirms no disagreement exists between the departing directors and the Company.
- No financial data or operational updates are included in this specific filing.